Korean molecular diagnostic company Gencurix Inc reported on Wednesday that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test, a diagnostic kit for COVID-19.
This is the second RT-PCR test launched by Gencurix following its first test assay, GenePro COVID-19 Detection Test, which was released in March.
Advantages of the GenePro SARS-CoV-2 Test include simultaneous monitoring of up to 384 samples, allowing high throughput screening of the novel coronavirus.
With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests across the United States.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial